By N. Giores. Bethany College, Scotts Valley, CA. 2018.
Comparative clinical responses to risperidone and divalproex in patients with pediatric bipolar disorder zudena 100mg without prescription. Atypical antipsychotic drugs Page 185 of 230 Final Report Update 3 Drug Effectiveness Review Project 427 buy zudena 100mg lowest price. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized purchase zudena 100mg, double-blind order zudena 100mg without prescription, placebo- controlled study buy generic zudena 100 mg on-line. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. Seo H-J, Jung Y-E, Woo YS, Jun T-Y, Chae J-H, Bahk W-M. Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M. Extended- release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Dunner DL, Amsterdam JD, Shelton RC, Loebel A, Romano SJ. Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study. A randomized, double-blind, and placebo- controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depression. Risperidone for treatment-refractory major depressive disorder: a randomized trial. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and Atypical antipsychotic drugs Page 186 of 230 Final Report Update 3 Drug Effectiveness Review Project residual depressive symptoms: a randomized, placebo-controlled pilot study. Effects of risperidone augmentation in patients with treatment-resistant depression: Results of open-label treatment followed by double-blind continuation. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. A novel augmentation strategy for treating resistant major depression. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. Yargic L, Corapcioglu A, Kocabasoglu N, Erdogan A, Koroglu G, Yilmaz D. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. International Journal of Psychiatry in Clinical Practice. The co-administration of quetiapine or placebo to cognitive-behavior therapy in treatment refractory depression: a preliminary trial. Atypical antipsychotic drugs Page 187 of 230 Final Report Update 3 Drug Effectiveness Review Project 453. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M.
Heterogeneity: The variation in or diversity of participants order zudena 100mg, interventions buy zudena 100 mg fast delivery, and measurement of outcomes across a set of studies discount 100mg zudena mastercard. Indirect analysis: The practice of using data from trials comparing one drug in a particular class or group to a drug outside that class or group or to placebo and attempting to draw conclusions about the comparative effectiveness of drugs within a class or group based on those data order zudena 100mg without prescription. For Topical calcineurin inhibitors Page 66 of 74 Final Report Drug Effectiveness Review Project example 100 mg zudena sale, using direct comparisons between drugs A and B and between drugs B and C to make indirect comparisons between drugs A and C. Intention to treat (ITT): The use of data from a randomized controlled trial in which data from all randomized patients are accounted for in the final results. Trials often report results as being based on intention to treat despite some patients being excluded from the analysis. Internal validity: The extent to which the design and conduct of a study are likely to have prevented bias. Generally, the higher the interval validity, the better the quality of the published study. Inter-rater reliability: The degree of stability exhibited when a measurement is repeated under identical conditions by different raters. Intermediate outcome: An outcome not of direct practical importance but believed to reflect outcomes that are important. For example, blood pressure is not directly important to patients but it is often used as an outcome in clinical trials because it is a risk factor for stroke and myocardial infarction. Mean difference: A method used to combine measures on continuous scales (such as weight), where the mean, standard deviation, and sample size in each group are known. Meta-analysis: The use of statistical techniques in a systematic review to integrate the results of included studies. Although they are sometimes used interchangeably, meta-analyses are not synonymous with systematic reviews. However, systematic reviews often include meta-analyses. Meta-regression: A technique used to explore the relationship between study characteristics (for example, concealment of allocation, baseline risk factors, or timing of the intervention) and study results (for example, the magnitude of effect observed in each study) in a systematic review. Multivariate analysis: Measuring the impact of more than one variable at a time while analyzing a set of data. N of 1 trial: A randomized trial in an individual to determine the optimum treatment for that individual. Noninferiority trial: A trial designed to determine whether the effect of a new treatment is not worse than a standard treatment by more than a prespecified amount. Nonrandomized study: Any study estimating the effectiveness of an intervention (harm or benefit) that does not use randomization to allocate patients to comparison groups. There are Topical calcineurin inhibitors Page 67 of 74 Final Report Drug Effectiveness Review Project many types of nonrandomized studies, including cohort studies, case-control studies, and before -after studies. Null hypothesis: The statistical hypothesis that one variable (for example, which treatment a study participant was allocated to receive) has no association with another variable or set of variables. Number needed to treat (NNT): An estimate of how many people need to receive a treatment before one person would experience a beneficial outcome. Observational study: A type of nonrandomized study in which the investigators do not intervene, instead simply observing the course of events. Odds ratio (OR): The ratio of the odds of an event in one group to the odds of an event in another group. One-tailed test: A hypothesis test in which the values for which we can reject the null hypothesis are located entirely in one tail of the probability distribution. For example, testing whether one treatment is better than another (rather than testing whether one treatment is either better or worse than another). Open-label trial: A clinical trial in which the investigator and participant are aware which intervention is being used for which participant (that is, a trial that is not blinded). Random allocation may or may not be used in open-label trials. Per protocol: The subset of participants from a randomized controlled trial who complied with the protocol sufficiently to ensure that their data would be likely to exhibit the effect of treatment. Per protocol analyses are sometimes misidentified in published trials as intention-to- treat analyses.
Patients on sitagliptin monotherapy had lower rates of total withdrawal relative to patients on glipizide buy 100mg zudena free shipping, who experienced more hypoglycemic events and higher rates of total withdrawal relative to patients on metformin cheap 100mg zudena otc. The rate of total withdrawals was also higher in patients whose add-on therapy was sitagliptin than in patients using monotherapy with metformin buy zudena 100mg without a prescription, pioglitazone discount 100 mg zudena with visa, or glimepiride buy zudena 100mg amex. The most commonly reported adverse events were hypoglycemia, abdominal pain, nausea, vomiting, and diarrhea. A total of 20 deaths were reported in 4 trials over 24-104 weeks. None was considered to be related to any study intervention; 8 were sudden cardiac deaths or myocardial infarctions, 2 were secondary to trauma, 1 was related to sepsis, 6 were due to cancer, 1 suicide, 1 was related to chronic obstructive pulmonary disease and interstitial lung disease, and 1 cause of death was unknown. Rare adverse events Sixteen randomized controlled trials reported adverse events. In those trials adverse events occurring in at least 4% of study subjects included: upper respiratory tract infections, headache, influenza, nasopharyngitis, and urinary tract infection. Incidence of adverse effects between sitagliptin and active comparator agents is summarized in Tables 49-50, and incidence of adverse effects between sitagliptin and placebo is summarized in Tables 52-53. Pooled relative risk for upper respiratory and urinary tract infections showed no significant difference between 42, 43, 45 34, sitagliptin and placebo (relative risk 1. Four studies 42, 47, 49 reported small increases (≤10% from baseline) in mean white blood cell count, mainly an increase in absolute neutrophil count, in regimens with sitagliptin compared to regimens without. These increases appeared early and remained stable throughout the duration of the studies. No other trials provided data on changes in white blood cell count with sitagliptin. Edema was only reported for 1 study and the incidence was 5% in the rosiglitazone group and 1% in both placebo 36 and sitagliptin groups. Hypoglycemia In general, hypoglycemia was more common in patients treated with comparator agents as opposed to sitagliptin. Pioglitazone was the only comparator that had lower incidence of hypoglycemia. Patients taking sitagliptin in addition to glimepiride experienced more hypoglycemia than those taking glimepiride alone. Similarly, patients taking sitagliptin in addition to insulin and metformin experienced more hypoglycemia than those taking insulin and metformin alone. There was no statistically significant difference in the overall risk of mild to moderate hypoglycemia between sitagliptin and placebo (pooled relative risk 1. The rate of mild-to-moderate hypoglycemia increased slightly when sitagliptin was added to glimepiride (7. Abdominal pain, nausea, vomiting, and diarrhea Compared with metformin monotherapy, sitagliptin was associated with lower incidence of abdominal pain, nausea, vomiting, and diarrhea (Tables 49-50). Combination therapy of sitagliptin plus glimepiride, metformin, or pioglitazone had <6% incidence of abdominal pain, nausea, vomiting, and diarrhea; these results were not significantly different from their comparisons (Tables 49-50). There were no statistically significant differences between sitagliptin monotherapy and 31, 42, 43, 45 placebo in the risk of nausea (pooled relative risk 1. However, based on the elevated relative risks, there appears to be a trend for greater risk of experiencing abdominal pain, and nausea with sitagliptin monotherapy compared with placebo. Lipids Six publications reported changes in lipid parameters in patients taking sitagliptin compared to 30, 32, 36, 46-48 placebo, rosiglitazone, pioglitazone, glipizide, and metformin (Tables 54-56). The data for the remaining 9 publications was received from the manufacturer. In 12 trials, patients taking sitagliptin had either less elevation or greater reduction in triglycerides than those in the comparator groups. Changes in all other lipid parameters were less significant and more variable across studies. The results of our meta-analyses comparing sitagliptin with placebo for lipid parameters are summarized in Table 51. For these analyses, we assumed a pre-post correlation of 0. There was no statistically significant difference for total cholesterol, HDL, or LDL in our main analyses or any of the related sensitivity analyses (Appendix E). For triglycerides, the main analysis favored sitagliptin (WMD -9. Adverse events of sitagliptin compared with oral hypoglycemic agents Scott, Williams-Herman, Williams- Nauck, 30 31 32 33 36 37 34 2007 Goldstein, 2006 2009 Herman, 2010 Scott, 2008 Chan, 2008 2007 S/ Glip/ Adverse event S100 Glip S100 M1 M2 S100 M1 M2 S100 M1 M2 S100 Rosi S25/50 Glip MET MET Treatment- emergent adverse events (%) a 1.
For acute use purchase zudena 100mg otc, 1 RCT showed no significant difference in hospital nd admissions or rescue medication use; a 2 RCT found no significant difference in symptoms 30 minutes after treatment proven 100 mg zudena. Comparisons specific to Comparisons of interest in Canada: Canada: Terbutaline compared with albuterol: Terbutaline compared Symptoms in pediatric asthma: NSD (3 studies) with albuterol: 1 good cheap zudena 100mg on-line, 3 EIB: 1 RCT showed fewer patients requiring fair RCTs; EIA: 1 fair RCT aminophylline treatment with terbutaline than with Fenoterol compared with albuterol (no statistics provided) IB: 1 RCT in a Cochrane review Fenoterol compared with IB in chronic Fenoterol compared with asthma: Symptoms: NSD (1 study in Cochrane albuterol: 0 RCTs review) Fenoterol compared with metaproterenol: 0 RCTs Terbutaline compared with fenoterol: 0 RCTs Terbutaline compared Quick-relief medications for asthma Page 32 of 113 Final Report Update 1 Drug Effectiveness Review Project Drugs compared: Number and quality of studies Findings with metaproterenol: 0 RCTs Terbutaline compared with pirbuterol: 0 RCTs Fenoterol compared with IB + fenoterol: 0 RCTs Pirbuterol compared with terbutaline: 0 Key Question 2 generic zudena 100mg on line. Adults Albuterol compared with Albuterol compared with levalbuterol: No What are the comparative levalbuterol: 3 fair cheap zudena 100 mg fast delivery, 1 poor significant difference in withdrawal rates (3 incidence and severity of RCT; 5 RCTs with AE studies). Heart rate increased with both drugs (3), adverse events reported data only greater with albuterol (1). No significant difference from using quick-relief in BP (1), palpitations (1), tachycardia (1), medications to treat Albuterol compared with increased blood glucose (1), or outpatients with albuterol + IB: Cochrane dizziness/nervousness/anxiety/tremor (6). In 5 bronchospasm due to review (7 RCTs) studies, decrease in K+ did not differ significantly asthma or to prevent or Albuterol compared with between drugs. Albuterol compared with albuterol + IB: In 7 RCTs in a Cochrane review, withdrawal rates were similar; no other comparative AE data. Comparisons specific to Comparisons of interest in Canada: Canada: Fenoterol compared with albuterol: BP Fenoterol compared with decreased 1-6 mm Hg (7 studies) after both albuterol: 1 poor RCT; 9 drugs; heart rate response varied (-5 to +15 BPM) RCTs with AE data only (9). Decrease in K+ was not significantly different Terbutaline compared between groups (2). Heart rate increased 5-15 Terbutaline compared BPM (NSD) (4). Terbutaline compared with fenoterol: Sparse data on comparative safety. Children Albuterol compared with Albuterol compared with levalbuterol: What are the comparative levalbuterol: 1 good, 3 fair Withdrawal rates varied (2 studies). Increase in incidence and severity of Albuterol compared with heart rate: NSD (3 studies). No adverse events reported pirbuterol: 1 RCT for AEs significant difference between drugs for tremor from using quick-relief only (1), light-headedness (1), dizziness (1), medications to treat Levalbuterol compared nervousness (1). Blood glucose increased with outpatients with with albuterol + IB: 1 fair both drugs, more with albuterol (1). Decrease in bronchospasm due to RCT K+: NSD (2); lower K+ with albuterol (1 study at nd asthma or to prevent or day 0, NSD day 21; 2 study, no data). For Quick-relief medications for asthma Page 33 of 113 Final Report Update 1 Drug Effectiveness Review Project Drugs compared: Number and quality of studies Findings treat exercise-induced Albuterol compared with Update1, rates of any AEs highest with albuterol, bronchospasm? Rates of tremor, nervousness, nausea, headache were not significantly different between groups. Albuterol compared with albuterol + IB: In two studies in the ED and one with regular use for 1 week, there were no significant differences in adverse events between treatment groups. Comparisons specific to Comparisons of interest in Canada: Canada: Fenoterol compared with albuterol: Minimal Fenoterol compared with reporting of adverse events in these studies. Terbutaline compared Terbutaline compared with albuterol: Heart with albuterol: 1 good, 3 rate response varied with no significant difference fair; 2 RCTs with AE data between drugs (3). No Terbutaline compared neurological comparative data. Terbutaline compared with pirbuterol: 0 Key Question 3. Adults and children Albuterol compared with Albuterol compared with levalbuterol: 2 RCTs Are there subgroups of levalbuterol: Age/sex: 0 in children and 2 in adults were predominately patients for which quick- studies African American populations seen in the ED. In relief medications used to Race: 2 studies in children 1 study showed decreased rate of treat outpatients with children, 2 studies in hospitalization with levalbuterol; the other showed bronchospasm due to adults no significant difference. In adults 1 RCT showed asthma or to prevent or no significant difference in hospitalization rates. Albuterol compared with albuterol + IB: In 1 RCT with a predominately African American population, subgroup analyses based on age or disease severity revealed no significant difference between groups (specific outcomes referred to are unclear). Quick-relief medications for asthma Page 34 of 113 Final Report Update 1 Drug Effectiveness Review Project Drugs compared: Number and quality of studies Findings Comparisons specific to Comparisons of interest in Canada: Canada: No data on subgroups identified. Abbreviations: AE, adverse events; BP, blood pressure; BPM, beats per minute; EIA, exercise-induced asthma; ED, emergency department; IB, ipratropium bromide; K+, serum potassium; MDI, metered dose inhaler; NSD, no significant difference; QID, four times a day; RCT, randomized controlled trial.
10 of 10 - Review by N. Giores
Votes: 52 votes
Total customer reviews: 52